

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation or abstract is attached.


document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here

→ Bope Robinson




<sup>1</sup>Only with ticked confirmation to applicant.  
<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.


→ Hope Returns

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/706,701
		Filing Date	November 12, 2003
		First Name Inventor	Lehmann, et al.
(Use several sheets if necessary)		Attorney Docket Number	21435 US
Sheet	1	of	3

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	A1	4,179,337		Davis et al.	12/18/1979
	A2	4,745,099		Akamatsu et al.	05/17/1988
	A3	5,272,071		Chappel	12/21/1993
	A4	5,324,650		Obzansky et al.	06/28/1994
	A5	5,359,030		Ekwuribe	10/25/1994
	A6	5,376,632		Konings et al.	12/27/1994
	A7	5,541,158		Vance et al.	07/30/1996
	A8	5,641,670		Treco et al.	06/24/1997
	A9	5,672,662		Harris et al.	09/30/1997
	A10	5,681,811		Ekwuribe	10/28/1997
	A11	5,733,746		Treco et al.	03/31/1998
	A12	5,733,761		Treco et al.	03/31/1998
	A13	5,981,214		Skoultchi	11/09/1999
	A14	5,994,127		Selden et al.	11/30/1999
	A15	6,333,306		Lehmann et al.	12/25/2001
	A16	6,340,742		Burg et al.	01/22/2002
	A17	6,372,715		Kaltwasser et al.	04/16/2002
	A18	6,528,313		Le Mouellic et al.	03/04/2003
	A19	6,583,272		Bailon	06/24/2003
	A20	US 2002/0160956 A1		Lehmann et al.	10/2002

FOREIGN PATENT DOCUMENTS							
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
H/K	B1	WO 93/09222			Transkaryotic Therapies, Inc.	05/13/1993	
	B2	WO 94/12650			Transkaryotic Therapies, Inc.	06/09/1994	
	B3	WO 95/31560			Transkaryotic Therapies, Inc.	11/23/1995	
	B4	WO 90/11354			Institut Pasteur	10/04/1990	
	B5	WO 91/06667			Cell Genesys Inc.	05/16/1991	
	B6	WO 91/09955			Applied Research Systems	07/11/1991	
	B7	WO 01/02017			F.Hoffmann-La Roche AG	01/11/2001	
	B8	EP 1064951			F.Hoffmann-La Roche AG	01/03/2001	
Examiner Signature	Dr. Eshwara				DATE CONSIDERED	8/29/05	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation or abstract is attached.




Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				<b>Complete if Known</b>	
				Application Number	10/706,701
				Filing Date	November 12, 2003
				First Name Inventor	Lehmann, et al.
Sheet	2	of	3	Attorney Docket Number	21435 US

### FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
AK	B9	EP 539167			Ortho Pharmaceutical Corp.	04/28/1993	
	B10	EP 605963			Ortho Pharmaceutical Corp.	07/13/1994	
	B11	WO 93/25212			Amgen Inc.	12/23/1993	
	B12	WO 94/20069			Amgen Inc.	09/15/1994	
	B13	WO 95/11924			Enzon, Inc.	05/04/1995	
	B14	EP 584876			Sterling Winthrop Inc.	03/02/1994	
	B15	WO 92/16555			Enzon, Inc.	10/01/1992	
	B16	WO 94/28024			Enzon, Inc.	12/08/1994	
	B17	WO 97/04796			Protein Delivery, Inc.	02/13/1997	
	B18	WO 98/32466			Polymasc Pharmaceutical PLC	07/30/1998	
	B19	DE 3924705			Boehringer Mannheim GmbH	01/31/1991	
	B20	WO 01/87329			F.Hoffmann-La Roche AG	11/22/2001	
	B21	EP 640619			Amgen Inc.	03/01/1995	
	B22	EP 0411678			Genetics Institute Inc.	02/06/1991	
	B23	EP 0205564			Genetics Institute Inc.	12/30/1986	
	B24	EP 0286439			Ortho Pharmaceutical Corp.	10/12/1988	
	B25	WO 97/09996			Boehringer Mannheim GmbH	03/20/1997	
	B26	WO 98/41226			Boehringer Mannheim GmbH	09/24/1998	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AK	C1	P. Lehmann, M. Volkmann, J. Lotz, A. Baldauf, R. Roeddiger, poster presented at the AACC/SCCC, Annual Meeting, July 29 - August 2, 2001, Chicago Illinois	
	C2	March J., Advanced Organic Chemistry, McGraw-Hill, 1977, pgs. 375-376	
	C3	Grasetti, D. R. & Murray, J. F., J. Appl. Biochem. Biotechnol. 119, pgs. 41-49, 1967	
	C4	Morpurgo M. et al., J. Bioconj. Chem. (1996) Vol. 7, pgs. 363-368	
	C5	Hermanson, G. T. Bioconjugate Techniques Academic Press, San Diego (1996) pgs. 147-148	
	C6	Annable, et al. Bull. Wild. Hlth. Org. (1972) Vol. 47 pgs. 99-112	
	C7	Abstract corresponding to WO 90/11354 (B4)	
	C8	Abstract corresponding to DE 3924705 (B19)	
Examiner Signature			DATE CONSIDERED 8/29/05

<sup>7</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Complete if Known</b>			
		Application Number	10/706,701		
		Filing Date	November 12, 2003		
		First Name Inventor	Lehmann, et al.		
Sheet	3	of	3	Attorney Docket Number	21435 US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AK	C9	Grützmacher P., et al., <i>Clinical Nephrology</i> , vol. 38, pp 92-97, 1992	
HAR	C10	Wick, M.; Pinggera, W.; Lehmann, P., <i>Eisenstoffwechsel Diagnostik und Therapie der Anämien</i> , 3 <sup>rd</sup> Edition, Springer, Wien, NY, pp 5-14, 38-55, 65-80, 94-98, Sept. 1996	
	C11	Sunder-Plassmann G., et al., <i>Journal of the American Society of Nephrology</i> , 5, (3), pp 478 (1994).	
	C12	Gasche C., et al., <i>Dig. Dis. Sci.</i> , 39, (9) pp 1930-4 (1994).	
	C13	Sunder-Plassmann G., et al., <i>Nephrology Dialysis Transplantation</i> , 10, (11), pp 2070-2076 (1995).	
	C14	Mercuriali F. et al., Erythropoiesis: <i>New Dimensions in the Treatment of Anaemia</i> , 6/3, pp 67-76, (1995).	
	C15	Sunder-Plassmann G., et al., <i>Nephrology Dialysis Transplantation</i> , 11, (9), pp 1797-1802, (1996).	
	C16	Taylor J. E., et al., <i>Nephrology Dialysis Transplantation</i> , 11, (6), pp 1079-1083, (1996).	
	C17	Breymann, et al., <i>Eur. J. Clin. Invest.</i> , pp 123-30.	
	C18	Goodnough, et al., <i>Haematology</i> , 1(2), pp 163-166.	
	C19	MacDougall (1994) Monitoring of Iron Status & Iron Supplementation in Patients Treated with Erythropoietin. <i>Current Opinion in Nephrology &amp; Hypertension</i> 3(6) pgs. 620-625	
	C20	Taylor et al. (1996) Regular low-dose Intravenous Iron Therapy Improves Response to Erythropoietin in Haemodialysis Patients. <i>Nephrology, Dialysis, &amp; Transplantation</i> 11(6) pgs. 1079-1083	
	C21	Means, Jr. (1995) Erythropoietin in the Treatment of Anemia in Chronic Infectious, Inflammatory, & Malignant Diseases. <i>Current Opinion in Hematology</i> 2(3) pgs. 210-213	
	C22	Adamson (1996) Erythropoietin, Iron Metabolism, & Red Blood Cell Production. <i>Seminars In Hematology</i> 33(2) pgs. 5-9	
	C23	Mercuriali & Inghilleri (1995) Iron Administration to Optimize the Effect of r-HuEPO in the Surgical Setting. Erythropoiesis: <i>New Dimensions in the Treatment of Anemia</i> 6(3) pgs. 67-76	
✓	C24	Pincus et al. (August, 1990) Multicultural Study of Recombinant Human Erythropoietin in Correction of Anemia in Rheumatoid Arthritis. <i>The American Journal of Medicine</i> 89(2) pgs. 161-168.	

Examiner Signature	<i>David Robinson</i>	DATE CONSIDERED	8/29/05
--------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

138866